首页 > 抗体蛋白 > 抗体
Alexa Fluor® 488 anti-mouse Ly-6G/Ly-6C (Gr-1)
产品名称:
Alexa Fluor® 488 anti-mouse Ly-6G/Ly-6C (Gr-1)
产品类别:
抗体
产品编号:
108419
产品应用:
108419
[价格]
规格 价格 库存
25µg ¥ 1414 1

产品详情

Product Details

Verified Reactivity
Mouse
Antibody Type
Monoclonal
Host Species
Rat
Immunogen
Raised against granulocytes of mouse origin
Formulation
Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide.
Preparation
The antibody was purified by affinity chromatography and conjugated with Alexa Fluor? 488 under optimal conditions.
Concentration
0.5 mg/ml
Storage & Handling
The antibody solution should be stored undiluted between 2°C and 8°C, and protected from prolonged exposure to light. Do not freeze.
Application

FC - Quality tested
IHC - Reported in the literature, not verified in house

Recommended Usage

Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is ≤ 0.25 ?g per 106 cells in 100 ?l volume. It is recommended that the reagent be titrated for optimal performance for each application.

* Alexa Fluor? 488 has a maximum emission of 519 nm when it is excited at 488 nm.


Alexa Fluor? and Pacific Blue? are trademarks of Life Technologies Corporation.

View full statement regarding label licenses
Excitation Laser
Blue Laser (488 nm)
Application Notes

Clone RB6-8C5 binds with high affinity to mouse Ly-6G molecules and to a lower extent to Ly-6C19. Clone RB6-8C5 impairs the binding of anti-mouse Ly-6G clone 1A819. However, clone RB6-8C5 is able to stain in the presence of anti-mouse Ly-6C clone HK1.420.

The RB6-8C5 antibody has been used to identify peripheral blood neutrophils and deplete granulocytes in vivo. Additional reported applications (for relevant formats of this clone) include: in vitro complement-mediated cytotoxicity2, in vivo depletion3-5,9, immunoprecipitation1, immunohistochemical staining6 (including paraffin-embedded sections9,16,33-35, acetone-fixed frozen sections11 and zinc-fixed sections15), and Western blotting7. RB6-8C5 is not suitable for depletion of hepatic myeloid derived suppressor cells (MDSCs)20.

Special Note:?For in vivo studies or highly sensitive assays, we recommend Ultra-LEAF? purified antibody (Cat. No. 108436).

Application References

(PubMed link indicates BioLegend citation)
  1. Fleming TJ, et al. 1993. J. Immunol. 151:2399. (IP)
  2. Brummer E, et al. 1984. J. Leukocyte Biol. 36:505. (CMCD)
  3. Stoppacciaro A, et al. 1993. J. Exp. Med. 178:151. (Deplete)
  4. Tumpey TM, et al. 1996. J. Virol. 70:898. (Deplete)
  5. Czuprynski CJ, et al. 1994. J. Immunol. 152:1836. (Deplete)
  6. Nitta H, et al. 1997. Cell Vision 4:73. (IHC)
  7. Jutila MA, et al. 1988. Eur. J. Immunol. 18:1819. (WB)
  8. Engwerda CR, et al. 2004. Am. J. Pathol. 165:2123.
  9. Brown CR, et al. 2004. Infect. Immun. 72:4956. (Deplete, IHC)
  10. Andoniou CE, et al. 2005. Nature Immunology 6:1011. (FC) PubMed
  11. Li M, et al. 2006. P. Natl. Acad. Sci USA 103:11736. (IHC)
  12. Dzhagalov I, et al. 2007. Blood 109:1620. (FC) PubMed
  13. Fazilleau N, et al. 2007. Nature Immunol. 8:753. (FC) PubMed
  14. Heuser M, et al. 2007. Blood 110:1639. (FC) PubMed
  15. Wang T, et al. 2007. Infect. Immun. 75:1144. (IHC)
  16. Bosio CM, et al. 2007. J. Immunol. 178:4538. (IHC)
  17. Boehme SA, et al. 2009. Int. Immunol. 21:81. (IHC)
  18. Piao Y, et al. 2012. Neuro Oncol. 14:1379. PubMed
  19. Ribechini E, et al. 2009. Eur. J. Immunol. 39:3538.
  20. Ma C, et al. 2012. J. Leukoc. Biol. 92:1199.
  21. Li J, et al. 2012. Arthritis Rheum. 64:1098. PubMed
  22. Fan Q, et al. 2014. Cancer Res. 74:471. PubMed
  23. Korrer MJ, et al. 2014. PLoS One. 9:91370. PubMed
  24. Morshed M, et al. 2014. J Immunol. 192:5314. PubMed
  25. Collins C, et al. 2014. PNAS. 111:9899. PubMed
  26. Madireddi S, et al. 2014. J Exp Med. 211:1433. PubMed
  27. Bianchi G, et al. 2014. Cell Death Dis. 5:1135. PubMed
  28. Guo H, et al. 2014. J Leukoc Biol. 96:419. PubMed
  29. Roderick JE, et al. 2014. PNAS. 111:14436. PubMed
  30. Distel E, et al. 2014. Circ Res. 115:759. PubMed
  31. Iwai H, et al. 2015. Tuberculosis. 95:246. PubMed
  32. Charmsaz S, et al. 2015. PLoS One. 10:130692. PubMed
  33. Whiteland J, et al. 1994 J Histochem Cytochem 43:3 (IHC-P)
  34. Brown C, et al. 2003 J Immunology 171:2 (IHC-P)
  35. Obregon-Henao A, et al. PLoS One 8:11 (IHC-P)
Product Citations
  1. Haratani K, et al. 2019. J Clin Invest. 130:374. PubMed
  2. Kimura S, et al. 2020. Nat Commun. 0.620833333. PubMed
  3. Chen CC, et al. 2018. Oncoimmunology. 7:e1424612. PubMed
  4. Cruz MA, et al. 2022. Nat Nanotechnol. 17:1004. PubMed
  5. Hu HJ, et al. 2020. Cell Death Dis. 1.168055556. PubMed
  6. Farsakoglu Y et al. 2019. Cell reports. 26(9):2307-2315 . PubMed
  7. Pingili AK, et al. 2021. Cell Reports. 35(12):109285. PubMed
  8. Yang W, et al. 2020. Nat Commun. 3.553472222. PubMed
  9. Isoda T et al. 2017. Cell. 171(1):103-119 . PubMed
  10. Onishi S, et al. 2015. PLoS One. 10:126564. PubMed
  11. Nasser MW, et al. 2015. Cancer Res . 75: 974-985. PubMed
  12. Krivanek J, et al. 2020. Nat Commun. 3.802777778. PubMed
  13. Oghumu S, et al. 2014. Immunology. 143: 109-119. PubMed
  14. Higa T, et al. 2022. Nat Commun. 13:1500. PubMed
  15. Magupalli VG, et al. 2020. Science. :369. PubMed
  16. Chen C, et al. 2019. Cell Rep. 29:4200. PubMed
  17. Mooney C, et al. 2017. International Journal of Molecular Sciences. 10.3390/ijms18051037. PubMed
  18. Hsieh C, et al. 2014. J Immunol. 193:3693. PubMed
  19. Hirano Y, et al. 2018. J Leukoc Biol. 104:1159. PubMed
  20. Huang YL, et al. 2021. Commun Biol. 4:229. PubMed
  21. Zhong W, et al. 2022. Nat Commun. 13:4390. PubMed
  22. Burkhardt A, et al. 2014. J Immunol. 193:1468. PubMed
  23. He J, et al. 2019. J Clin Invest. 130. PubMed
  24. Loh Z, et al. 2020. PLOS Pathogens. 16(7):e1008651. PubMed
  25. Haas MS, et al. 2020. Mol Cancer Res. 19:717. PubMed
  26. Boltersdorf T, et al. 2020. Theranostics. 10:6599. PubMed
  27. Wang H, et al. 2020. Nat Mater. 1.655555556. PubMed
  28. Hu M, et al. 2020. Cancer Immunol Res. 8:1150. PubMed
  29. Sasi S, et al. 2014. J Biol Chem. 289:14178. PubMed
  30. Moon H, et al. 2019. Nat Commun. 10:2225. PubMed
  31. Liu Y, et al. 2022. iScience. 25:105121. PubMed
  32. Jiang L, et al. 2020. Cell. 183(5):1219-1233.e18. PubMed
  33. von Roemeling CA, et al. 2020. Nat Commun. 11:1508. PubMed
  34. Liu Q, et al. 2021. Adv Mater. 33:e2102852. PubMed
  35. Wang X, et al. 2021. Sci Transl Med. 13:. PubMed
  36. Li J, et al. 2022. Nat Commun. 13:1481. PubMed
  37. Rahman H, et al. 2020. J Invest Dermatol. . PubMed
  38. Hsing CH, et al. 2021. Biomedicines. 9:. PubMed
  39. Tseng SH, et al. 2021. J Biomed Sci. 28:63. PubMed
RRID
AB_493480 (BioLegend Cat. No. 108419) AB_389309 (BioLegend Cat. No. 108417)

Antigen Details

Structure
21-25 kD
Distribution

Granulocytes, monocytes

Cell Type
Granulocytes, Monocytes, Neutrophils
Biology Area
Immunology, Innate Immunity
Antigen References

1. Fleming TJ, et al. 1993. J. Immunol. 151:2399.
2. Jutila MA, et al. 1988. Eur. J. Immunol. 18:1819.
3. Goni O, et al. 2002. Int. Immunol. 14:1125.

Gene ID
17067 View all products for this Gene ID 546644 View all products for this Gene ID
UniProt
View information about Ly-6G Ly-6C on UniProt.org

联系我们

TEL:021-34661275  点击拨打热线